COM.TO - Cardiome Pharma Corp.

Toronto - Toronto Delayed Price. Currency in CAD

Cardiome Pharma Corp.

1441 Creekside Drive
6th Floor
Vancouver, BC V6J 4S7

Full Time Employees163

Key Executives

NameTitlePayExercisedYear Born
Dr. William L. HunterPres, CEO & Director1.34MN/A1963
Ms. Sheila M. Grant MBAChief Operating Officer394kN/AN/A
Mr. David D. McMastersGen. Counsel540.52kN/A1959
Mr. Hugues SachotChief Commercial Officer598.17kN/AN/A
Mr. Justin A. RenzChief Financial OfficerN/AN/A1972
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

Corporate Governance

Cardiome Pharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.